Targeted Alpha-Particle Therapy for Hematologic Malignancies
نویسندگان
چکیده
منابع مشابه
Targeted therapy for hematologic malignancies.
BACKGROUND The introduction of monoclonal antibodies, either as native molecules or conjugated to radioisotopes or other toxins, has led to new therapeutic options for patients with hematologic malignancies. In addition, the use of small molecules against specific cell surface receptors, enzymes, and proteins has become an important strategy in the treatment of such disorders. METHODS The aut...
متن کاملCAR T-cell Therapy of Hematologic Malignancies: An Update in Targeted Antigens
Immunotherapy with genetically engineered T-cells that express the chimeric antigen receptor (CAR) has raised hopes for the treatment of pediatric malignancies. Although CAR T-cell development is on a fast-moving pace and evolution, the context of exploring novel targetable antigens has been neglected. In this review study, we analyze the prominent hematologic antigens targeted by engineered T-...
متن کاملHematologic malignancies: an opportunity for targeted drug therapy.
The Oncologist 2001;6(suppl 5):1-3 www.TheOncologist.com Correspondence: Janice L. Gabrilove, M.D., Chief, Division of Medical Oncology, Department of Medicine, Deputy Director for Clinical Affairs, The Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029, USA. Telephone: 212-241-9650; Fax: 212-289-0678; e-mail: [email protected] Received Septembe...
متن کاملMolecular-Targeted Therapies for Hematologic Malignancies
© 2012 Kevin D. Bunting et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported License ( http://creativecommons.org/licenses/by/3.0/), which permits making multiple copies, distribution, public display, and publicly performance, distribution of derivative works, provided the original work is properly cited. This license requires credit...
متن کاملIL13RA2 targeted alpha particle therapy against glioblastomas
Glioblastoma (GBM) is the most aggressive primary malignant brain cancer that invariably results in a dismal prognosis. Chemotherapy and radiotherapy have not been completely effective as standard treatment options for patients due to recurrent disease. We and others have therefore developed molecular strategies to specifically target interleukin 13 receptor alpha 2 (IL13RA2), a GBM restricted ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Medical Imaging and Radiation Sciences
سال: 2019
ISSN: 1939-8654
DOI: 10.1016/j.jmir.2019.05.008